Cargando…

Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster head...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gklinos, Panagiotis, Mitsikostas, Dimos D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222235/ https://www.ncbi.nlm.nih.gov/pubmed/32426040 http://dx.doi.org/10.1177/1756286420918088

Ejemplares similares

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Galcanezumab for the Management of Migraine: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
por: Abu-Zaid, Ahmed, et al.
Publicado: (2020)

Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
por: Zhao, Xiuyuan, et al.
Publicado: (2020)

Galcanezumab for migraine
Publicado: (2020)

Correction to: Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
por: Zhao, Xiuyuan, et al.
Publicado: (2021)

Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
por: Kuruppu, Dulanji K., et al.
Publicado: (2021)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
por: Yang, Yanbo, et al.
Publicado: (2020)

Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
por: Martin, Vincent, et al.
Publicado: (2020)

New players in the preventive treatment of migraine
por: Mitsikostas, Dimos D., et al.
Publicado: (2015)

Monoclonal Antibodies as Neurological Therapeutics
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
por: Detke, Holland C., et al.
Publicado: (2018)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Corasaniti, Maria Tiziana, et al.
Publicado: (2023)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Photophobia and migraine outcome during treatment with galcanezumab
por: Schiano di Cola, Francesca, et al.
Publicado: (2023)

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
por: Ford, Janet H., et al.
Publicado: (2019)

Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
por: Igarashi, Hisaka, et al.
Publicado: (2022)

B-Cell Targeted Therapies in Patients with Multiple Sclerosis and Incidence of Headache: A Systematic Review and Meta-Analysis
por: Mavridis, Theodoros, et al.
Publicado: (2022)

Treating primary headaches – management of migraine
por: Mitsikostas, Dimos D
Publicado: (2013)

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
por: Hu, Bo, et al.
Publicado: (2022)

Effectiveness of Physical Activity in Primary Prevention of Anxiety: Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Moreno-Peral, Patricia, et al.
Publicado: (2022)

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
por: Goadsby, Peter J, et al.
Publicado: (2019)

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Allopurinol for Secondary Prevention in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Ye, Yuyang, et al.
Publicado: (2023)

Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy
por: Lupi, Chiara, et al.
Publicado: (2019)

Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
por: Tatsuoka, Yoshihisa, et al.
Publicado: (2021)

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
por: Ruff, D. D., et al.
Publicado: (2019)

Melatonin or Ramelteon for Delirium Prevention in the Intensive Care Unit: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Aiello, Giuseppe, et al.
Publicado: (2023)

Pharmacologic Interventions to Prevent Delirium in Trauma Patients: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Zitikyte, Gabriele, et al.
Publicado: (2023)

Myoinositols Prevent Gestational Diabetes Mellitus and Related Complications: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Greff, Dorina, et al.
Publicado: (2023)

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
por: Stauffer, Virginia L., et al.
Publicado: (2019)

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
por: Martinez, James M, et al.
Publicado: (2020)

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
por: Takizawa, Tsubasa, et al.
Publicado: (2022)

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments
por: Kuruppu, Dulanji K., et al.
Publicado: (2021)

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
por: Ford, Janet H., et al.
Publicado: (2020)

Cognitive Behavioral Therapy for Migraine Headache: A Systematic Review and Meta-Analysis
por: Bae, Ji-yong, et al.
Publicado: (2021)

The durable effect of acupuncture for episodic migraine: a systematic review and meta-analysis
por: Shi, Hangyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_88nu6bcu1dig33shd6hu3m52f4